Cargando…
Real-world utilization patterns and outcomes of colesevelam hcl in the ge electronic medical record
BACKGROUND: In randomized controlled trials (RCTs), colesevelam HCI, added to other anti-diabetic therapy, reduced hemoglobin A1C by approximately 0.3% to 0.4% over 16- to 26-weeks compared with an increase of approximately 0.1% to 0.2% for placebo, for a placebo-adjusted treatment effect of approxi...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3750408/ https://www.ncbi.nlm.nih.gov/pubmed/23866087 http://dx.doi.org/10.1186/1472-6823-13-24 |